Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025.

Below are some of the key financial performance metrics for the Company.

1. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024.
   
   
   
    
2. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please see a more detailed explanation Adjusted EBITDA at the bottom of this press release.
   
   
   
    
3. Positive operating cash flow - Precipio will report $368K of positive operating cash flow during Q4-2025, and a total of $688K for 2025. This is compared to $439K of cash generated from operations in 2024. These amounts include certain unusual items related to Change Healthcare transactions and the COVID-related Employee Retention Credit. Excluding the unusual items, the Company's adjusted operating cash flow was $617K for Q4-2025 and a total of $727K for 2025.
    

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.